08 July 2024 : Clinical Research
Optimal Surgical Approaches for Thyroid Cancer: A Comparative Analysis of Efficacy and Complications
Abbas Aras
1ABDEF*, Ali R. Karayıl 2BCG
DOI: 10.12659/MSM.942619
Med Sci Monit 2024; 30:e942619
Table 2 Odds ratios for malignancy in the completion thyroidectomy after hemithyroidectomy group (CTx-HTx), logistic regression analysis results.
| Unadjusted | Nagelkerke R2 | Adjusted | Nagelkerke R2 | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |||
| Age, >45 | 1.015 (0.270–3.821) | 0.982 | 0.000 | 0.983 (0.259–3.734) | 0.980* | 0.007 |
| Sex, Male | 1.440 (0.372–5.581) | 0.598 | 0.007 | 1.442 (0.370–5.625) | 0.598** | 0.007 |
| Thyroid ca history in family | 1.111 (0.198–6.239) | 0.905 | 0.000 | 1.043 (0.170–6.398) | 0.964# | 0.007 |
| Tumor size(1) | ||||||
| 1–4 cm | 0.933 (0.090–9.695) | 0.954 | 0.000 | 0.667 (0.058–7.692) | 0.746# | 0.036 |
| >4 cm | 0.889 (0.061–12.885) | 0.931 | 0.722 (0.047–11.076) | 0.815# | ||
| Capsular invasion | 1.048 (0.265–4.149) | 0.947 | 0.000 | 1.050 (0.257–4.286) | 0.945# | 0.033 |
| Vascular invasion | 0.571 (0.062–5.256) | 0.621 | 0.008 | 0.415 (0.039–4.448) | 0.467# | 0.051 |
| Extrathyroidal invasion | 1.900 (0.311–11.591) | 0.487 | 0.014 | 1.901 (0.305–11.867) | 0.492# | 0.046 |
| Multicentric | 2.204 (0.456–10.661) | 0.326 | 0.027 | 1.971 (0.394–9.862) | 0.409# | 0.053 |
| Lymph node metastasis | 1.481 (0.138–15.941) | 0.746 | 0.003 | 1.017 (0.073–14.110) | 0.990# | 0.033 |
| Thyroglobulin, ≥30 ng/mL | 1.273 (0.120–13.460) | 0.841 | 0.001 | 1.678 (0.145–19.441) | 0.679# | 0.024 |
| Pathology result, 1 surgery(2) | ||||||
| Papillary microcarcinoma | 0.813 (0.083–7.982) | 0.859 | 0.001 | 0.896 (0.087–9.202) | 0.926# | 0.007 |
| Follicular thyroid carcinoma | 1.083 (0.103–11.403) | 0.947 | 1.086 (0.103–11.490) | 0.945# | ||
| (1) Reference category: (2) Reference category: Papillary thyroid carcinoma. * Adjusted by sex; ** Adjusted by age; # Adjusted by age and sex. OR – odds ratio; CI – confidence interval. | ||||||